Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Vical teams up with AnGes to develop new HBV treatment; shares ahead 7% premarket

Published 10/24/2017, 08:04 AM
Updated 10/24/2017, 08:04 AM
© Reuters.  Vical teams up with AnGes to develop new HBV treatment; shares ahead 7% premarket
  • Vical (NASDAQ:VICL) announces a joint development program with strategic partner AnGes aimed at a novel treatment for chronic hepatitis B virus (HBV) infection based on its DNA and lipid-delivery technologies.
  • The first stage of the partnership will be to demonstrate preclinical proof of concept for inhibiting HBV infection in a human liver model in H2 2018.
  • Osaka, Japan-based AnGes has provided partial funding for the initial work and Vical expects it to continue its financial support if it is successful. AnGes has the right of first refusal for an exclusive license to develop and commercialize the therapy in Japan.
  • The ultimate goal is to show the eradication of persistent HBV infection in chronic patients.
  • Shares are up 7% premarket on light volume.
  • Now read: Global Blood Therapeutics Drops Idiopathic Pulmonary Fibrosis, But Sickle Cell Disease Is At The Forefront


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.